{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:31:53Z","timestamp":1791937913554,"version":"4.3.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Introduction<\/jats:title>\n<jats:p>Local ablative treatment strategies are frequently offered to patients diagnosed with oligometastatic disease. Stereotactic body radiotherapy (SBRT), as ablative treatment option, is well established for lung and liver metastases, whereas for isolated adrenal gland metastases the level of evidence is scarce.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Material and methods<\/jats:title>\n<jats:p>This single-institution analysis of oligometastatic or oligoprogressive disease was limited to patients who received SBRT to adrenal metastasis between 2012 and 2019. Patient, tumor, treatment characteristics, and dosimetric parameters were analyzed for evaluation of their effect on survival outcomes.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>During the period of review 28 patients received ablative SBRT to their adrenal gland metastases. Most common primary tumors were non-small cell lung cancers (46%) with most patients diagnosed with a single adrenal gland metastasis (61%), which occurred after a median time of 14\u2009months. SBRT was delivered to a median biological effective dose at \u03b1\/\u03b2 of 10 (BED<jats:sub>10<\/jats:sub>) of 75\u2009Gy (range: 58\u2013151\u2009Gy). Median gross tumor volume (GTV) and median planning target volume (PTV) were 42 and 111\u2009mL, respectively. The homogeneity and conformity indices were 1.17 (range: 1.04\u20131.64) and 0.5 (range: 0.4.0.99), respectively, with the conformity index being affected by dose restrictions to organs at risk (OARs) in 50% of the patients. Overall response rate based on RECIST criteria was 86% (CR\u2009=\u200929%, PR\u2009=\u200957%) with 2-year local control (LC) of 84.8%, 2-year progression-free survival (PFS) of 26.3%, and 1-and 2-year overall survival (OS) of 46.6 and 32.0%, respectively. During follow up, only two local recurrences occurred. A trend for superior LC was seen if BED<jats:sub>10<\/jats:sub> was \u226575Gy (<jats:italic>p<\/jats:italic>\u2009=\u20090.101) or if the PTV was &lt;\u2009100\u2009ml (<jats:italic>p<\/jats:italic>\u2009=\u20090.072). SBRT was tolerated well with only mild toxicity.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>SBRT for adrenal metastases resulted in promising LC with low toxicity. Treatment response appeared to be superior, if SBRT was applied with higher BED. As the close proximity of OARs often limits the application of sufficiently high doses, further dose escalations strategies and techniques should be investigated in future.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13014-020-1480-0","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T15:03:04Z","timestamp":1580828584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8402-6694","authenticated-orcid":false,"given":"Laila","family":"K\u00f6nig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias F.","family":"H\u00e4fner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan A.","family":"Koerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Tonndorf-Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"von Nettelbladt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Weykamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Hoegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kl\u00fcter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Susko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"H\u00f6rner-Rieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,4]]},"reference":[{"issue":"1","key":"1480_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1158\/ajc.1938.57","volume":"32","author":"DA Glomset","year":"1938","unstructured":"Glomset DA. The incidence of metastasis of malignant tumors to the adrenals. Am J Cancer. 1938;32(1):57\u201361. https:\/\/doi.org\/10.1158\/ajc.1938.57.","journal-title":"Am J Cancer"},{"issue":"1","key":"1480_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1046\/j.0300-0664.2001.01435.x","volume":"56","author":"K-Y Lam","year":"2002","unstructured":"Lam K-Y, Lo C-Y. Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital. Clin Endocrinol. 2002;56(1):95\u2013101. https:\/\/doi.org\/10.1046\/j.0300-0664.2001.01435.x.","journal-title":"Clin Endocrinol"},{"issue":"4","key":"1480_CR3","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.adro.2017.07.011","volume":"2","author":"K Plichta","year":"2017","unstructured":"Plichta K, Camden N, Furqan M, et al. SBRT to adrenal metastases provides high local control with minimal toxicity. Adv Radiat Oncol. 2017;2(4):581\u20137. https:\/\/doi.org\/10.1016\/j.adro.2017.07.011.","journal-title":"Adv Radiat Oncol"},{"issue":"6","key":"1480_CR4","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.rpor.2015.05.009","volume":"20","author":"E Ippolito","year":"2015","unstructured":"Ippolito E, D'Angelillo RM, Fiore M, et al. SBRT: A viable option for treating adrenal gland metastases. Rep Pract Oncol Radiother. 2015;20(6):484\u201390. https:\/\/doi.org\/10.1016\/j.rpor.2015.05.009 PubMed PMID: 26696789; PubMed Central PMCID: PMCPMC4661344.","journal-title":"Rep Pract Oncol Radiother"},{"issue":"12","key":"1480_CR5","first-page":"801","volume":"57","author":"T Soejima","year":"1997","unstructured":"Soejima T, Hirota S, Hishikawa Y, et al. Radiation therapy for adrenal metastases. Nihon Igaku Hoshasen Gakkai Zasshi. 1997;57(12):801\u20134 PubMed PMID: 9394569.","journal-title":"Nihon Igaku Hoshasen Gakkai Zasshi"},{"issue":"6","key":"1480_CR6","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1002\/1097-0142(19900315)65:6<1318::aid-cncr2820650611>3.0.co;2-h","volume":"65","author":"EM Soffen","year":"1990","unstructured":"Soffen EM, Solin LJ, Rubenstein JH, et al. Palliative radiotherapy for symptomatic adrenal metastases. Cancer. 1990;65(6):1318\u201320. https:\/\/doi.org\/10.1002\/1097-0142(19900315)65:6<1318::aid-cncr2820650611>3.0.co;2-h PubMed PMID: 2155051.","journal-title":"Cancer."},{"issue":"1","key":"1480_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8\u201310 PubMed PMID: 7799047.","journal-title":"J Clin Oncol"},{"issue":"1066","key":"1480_CR8","doi-asserted-by":"publisher","first-page":"20160251","DOI":"10.1259\/bjr.20160251","volume":"89","author":"P Cheung","year":"2016","unstructured":"Cheung P. Stereotactic body radiotherapy for oligoprogressive cancer. Br J Radiol. 2016;89(1066):20160251. https:\/\/doi.org\/10.1259\/bjr.20160251 PubMed PMID: 27556349; eng.","journal-title":"Br J Radiol"},{"issue":"2","key":"1480_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jtho.2016.10.012","volume":"12","author":"C Kim","year":"2017","unstructured":"Kim C, Hoang CD, Kesarwala AH, et al. Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non\u2013Small Cell Lung Cancer. J Thorac Oncol. 2017;12(2):179\u201393. https:\/\/doi.org\/10.1016\/j.jtho.2016.10.012.","journal-title":"J Thorac Oncol"},{"issue":"18","key":"1480_CR10","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/JCO.19.00201","volume":"37","author":"DR Gomez","year":"2019","unstructured":"Gomez DR, Tang C, Zhang J, et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non\u2013Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019;37(18):1558\u201365. https:\/\/doi.org\/10.1200\/JCO.19.00201.","journal-title":"J Clin Oncol"},{"issue":"10185","key":"1480_CR11","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(18)32487-5.","journal-title":"Lancet"},{"issue":"5","key":"1480_CR12","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.surg.2018.11.008","volume":"165","author":"FT Drake","year":"2019","unstructured":"Drake FT, Beninato T, Xiong MX, et al. Laparoscopic adrenalectomy for metastatic disease: Retrospective cohort with long-term, comprehensive follow-up. Surgery. 2019;165(5):958\u201364. https:\/\/doi.org\/10.1016\/j.surg.2018.11.008.","journal-title":"Surgery"},{"issue":"12","key":"1480_CR13","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1245\/s10434-007-9569-3","volume":"14","author":"QY Duh","year":"2007","unstructured":"Duh QY. Laparoscopic adrenalectomy for isolated adrenal metastasis: the right thing to do and the right way to do it. Ann Surg Oncol. 2007;14(12):3288\u20139. https:\/\/doi.org\/10.1245\/s10434-007-9569-3 PubMed PMID: 17896147; PubMed Central PMCID: PMCPMC2077915.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"1480_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/(SICI)1098-2388(199906)16:4<293::AID-SSU4>3.0.CO;2-E","volume":"16","author":"BT Heniford","year":"1999","unstructured":"Heniford BT, Arca MJ, Walsh RM, et al. Laparoscopic adrenalectomy for cancer. Semin Surg Oncol. 1999;16(4):293\u2013306 PubMed PMID: 10332775.","journal-title":"Semin Surg Oncol"},{"issue":"4","key":"1480_CR15","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3892\/ol.2012.595","volume":"3","author":"QY Zheng","year":"2012","unstructured":"Zheng QY, Zhang GH, Zhang Y, et al. Adrenalectomy may increase survival of patients with adrenal metastases. Oncol Lett. 2012;3(4):917\u201320. https:\/\/doi.org\/10.3892\/ol.2012.595 PubMed PMID: 22741018; PubMed Central PMCID: PMCPMC3362489.","journal-title":"Oncol Lett"},{"issue":"7","key":"1480_CR16","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.ctrv.2014.04.001","volume":"40","author":"A Gunjur","year":"2014","unstructured":"Gunjur A, Duong C, Ball D, et al. Surgical and ablative therapies for the management of adrenal \u2018oligometastases\u2019 - a systematic review. Cancer Treat Rev. 2014;40(7):838\u201346. https:\/\/doi.org\/10.1016\/j.ctrv.2014.04.001 PubMed PMID: 24791623.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"1480_CR17","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12885-018-4191-2","volume":"18","author":"N Andratschke","year":"2018","unstructured":"Andratschke N, Alheid H, Allg\u00e4uer M, et al. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases [journal article]. BMC Cancer. 2018;18(1):283. https:\/\/doi.org\/10.1186\/s12885-018-4191-2.","journal-title":"BMC Cancer"},{"issue":"1","key":"1480_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s00066-013-0450-y","volume":"190","author":"M Guckenberger","year":"2014","unstructured":"Guckenberger M, Andratschke N, Alheit H, et al. Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol. 2014;190(1):26\u201333. https:\/\/doi.org\/10.1007\/s00066-013-0450-y PubMed PMID: 24052011; PubMed Central PMCID: PMC3889283.","journal-title":"Strahlenther Onkol"},{"key":"1480_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.lungcan.2016.04.012","volume":"97","author":"J Rieber","year":"2016","unstructured":"Rieber J, Streblow J, Uhlmann L, et al. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-a pooled analysis of the German working group \u201cstereotactic radiotherapy\u201d. Lung Cancer. 2016;97:51\u20138. https:\/\/doi.org\/10.1016\/j.lungcan.2016.04.012 PubMed PMID: 27237028.","journal-title":"Lung Cancer"},{"issue":"10","key":"1480_CR20","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s00066-014-0714-1","volume":"190","author":"F Sterzing","year":"2014","unstructured":"Sterzing F, Brunner TB, Ernst I, et al. Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO working group on stereotactic radiotherapy. Strahlenther Onkol. 2014;190(10):872\u201381. https:\/\/doi.org\/10.1007\/s00066-014-0714-1 PubMed PMID: 25091267.","journal-title":"Strahlenther Onkol"},{"issue":"8","key":"1480_CR21","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.21873\/anticanres.12788","volume":"38","author":"D Buergy","year":"2018","unstructured":"Buergy D, Rabe L, Siebenlist K, et al. Treatment of Adrenal Metastases with Conventional or Hypofractionated Image-guided Radiation Therapy - Patterns and Outcomes. Anticancer Res. 2018;38(8):4789\u201396. https:\/\/doi.org\/10.21873\/anticanres.12788 PubMed PMID: 30061250.","journal-title":"Anticancer Res"},{"key":"1480_CR22","doi-asserted-by":"publisher","first-page":"153303381880998","DOI":"10.1177\/1533033818809983","volume":"17","author":"N Katoh","year":"2018","unstructured":"Katoh N, Onishi H, Uchinami Y, et al. Real-Time Tumor-Tracking Radiotherapy and General Stereotactic Body Radiotherapy for Adrenal Metastasis in Patients With Oligometastasis. Technol Cancer Res Treat. 2018;17:1533033818809983. https:\/\/doi.org\/10.1177\/1533033818809983 PubMed PMID: 30407123; PubMed Central PMCID: PMCPMC6259059.","journal-title":"Technol Cancer Res Treat"},{"issue":"4","key":"1480_CR23","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.adro.2018.05.006","volume":"3","author":"DAS Toesca","year":"2018","unstructured":"Toesca DAS, Koong AJ, von Eyben R, et al. Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity. Adv Radiat Oncol. 2018;3(4):621\u20139. https:\/\/doi.org\/10.1016\/j.adro.2018.05.006 PubMed PMID: 30370363; PubMed Central PMCID: PMCPMC6200881.","journal-title":"Adv Radiat Oncol"},{"issue":"5","key":"1480_CR24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/COC.0b013e3182569189","volume":"36","author":"KA Ahmed","year":"2013","unstructured":"Ahmed KA, Barney BM, Macdonald OK, et al. Stereotactic body radiotherapy in the treatment of adrenal metastases. Am J Clin Oncol. 2013;36(5):509\u201313. https:\/\/doi.org\/10.1097\/COC.0b013e3182569189 PubMed PMID: 22781389.","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"1480_CR25","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.ijrobp.2010.11.060","volume":"82","author":"F Casamassima","year":"2012","unstructured":"Casamassima F, Livi L, Masciullo S, et al. Stereotactic radiotherapy for adrenal gland metastases: university of Florence experience. Int J Radiat Oncol Biol Phys. 2012;82(2):919\u201323. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.11.060 PubMed PMID: 21300473.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1480_CR26","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1016\/j.prro.2016.09.005","volume":"7","author":"WW Chance","year":"2017","unstructured":"Chance WW, Nguyen QN, Mehran R, et al. Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity. Pract Radiat Oncol. 2017;7(3):e195\u2013203. https:\/\/doi.org\/10.1016\/j.prro.2016.09.005 PubMed PMID: 27743801.","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"1480_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijrobp.2008.10.079","volume":"75","author":"S Chawla","year":"2009","unstructured":"Chawla S, Chen Y, Katz AW, et al. Stereotactic body radiotherapy for treatment of adrenal metastases. Int J Radiat Oncol Biol Phys. 2009;75(1):71\u20135. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.10.079 PubMed PMID: 19250766.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1480_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.clon.2017.09.007","volume":"30","author":"GG Hanna","year":"2018","unstructured":"Hanna GG, Murray L, Patel R, et al. UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy. Clinical Oncol. 2018;30(1):5\u201314. https:\/\/doi.org\/10.1016\/j.clon.2017.09.007.","journal-title":"Clinical Oncol"},{"issue":"3","key":"1480_CR29","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.ijrobp.2007.10.059","volume":"70","author":"C Park","year":"2008","unstructured":"Park C, Papiez L, Zhang S, et al. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70(3):847\u201352. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.10.059 PubMed PMID: 18262098.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1480_CR30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4103\/0971-6203.103606","volume":"37","author":"T Kataria","year":"2012","unstructured":"Kataria T, Sharma K, Subramani V, et al. Homogeneity Index: An objective tool for assessment of conformal radiation treatments. J Med Phys. 2012;37(4):207\u201313. https:\/\/doi.org\/10.4103\/0971-6203.103606 PubMed PMID: 23293452; PubMed Central PMCID: PMCPMC3532749.","journal-title":"J Med Phys"},{"issue":"5","key":"1480_CR31","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/0360-3016(93)90548-a","volume":"27","author":"E Shaw","year":"1993","unstructured":"Shaw E, Kline R, Gillin M, et al. Radiation therapy oncology group: radiosurgery quality assurance guidelines. Int J Radiat Oncol Biol Phys. 1993;27(5):1231\u20139. https:\/\/doi.org\/10.1016\/0360-3016(93)90548-a PubMed PMID: 8262852.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1480_CR32","doi-asserted-by":"publisher","unstructured":"Al-Shafa F, Arifin AJ, Rodrigues GB, et al. A Review of Ongoing Trials of Stereotactic Ablative Radiotherapy for Oligometastatic Cancers: Where Will the Evidence Lead? [Mini Review]. Front Oncol. 2019 9(543). doi: https:\/\/doi.org\/10.3389\/fonc.2019.00543. English.","DOI":"10.3389\/fonc.2019.00543"},{"issue":"12","key":"1480_CR33","first-page":"2058","volume":"45","author":"R Kumar","year":"2004","unstructured":"Kumar R, Xiu Y, Yu JQ, et al. 18F-FDG PET in Evaluation of Adrenal Lesions in Patients with Lung Cancer. J Nucl Med. 2004;45(12):2058\u201362.","journal-title":"J Nucl Med"},{"issue":"1","key":"1480_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1200\/jop.2017.026500","volume":"14","author":"SJ Stephens","year":"2018","unstructured":"Stephens SJ, Moravan MJ, Salama JK. Managing patients with Oligometastatic non\u2013small-cell lung Cancer. J Oncol Pract. 2018;14(1):23\u201331. https:\/\/doi.org\/10.1200\/jop.2017.026500 PubMed PMID: 29324212.","journal-title":"J Oncol Pract"},{"issue":"02","key":"1480_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.17925\/OHR.2017.13.02.117","volume":"13","author":"Bryce Thomsen","year":"2017","unstructured":"Thomsen B, Fairchild A. Adrenal Oligometastases Secondary to Non-small Cell Lung Cancer\u2014What is the Optimal Treatment Approach? Oncol Hematol Rev. 2017;13(117). https:\/\/doi.org\/10.17925\/OHR.2017.13.02.117.","journal-title":"Oncology & Hematology Review (US)"},{"issue":"3","key":"1480_CR36","doi-asserted-by":"publisher","first-page":"217","DOI":"10.7785\/tcrt.2012.500320","volume":"12","author":"S Rudra","year":"2013","unstructured":"Rudra S, Malik R, Ranck MC, et al. Stereotactic body radiation therapy for curative treatment of adrenal metastases. Technol Cancer Res Treat. 2013;12(3):217\u201324. https:\/\/doi.org\/10.7785\/tcrt.2012.500320 PubMed PMID: 23369155.","journal-title":"Technol Cancer Res Treat"},{"issue":"3","key":"1480_CR37","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s00066-018-1390-3","volume":"195","author":"K Burjakow","year":"2019","unstructured":"Burjakow K, Fietkau R, Putz F, et al. Fractionated stereotactic radiation therapy for adrenal metastases: contributing to local tumor control with low toxicity. Strahlenther Onkol. 2019;195(3):236\u201345. https:\/\/doi.org\/10.1007\/s00066-018-1390-3 PubMed PMID: 30374590.","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"1480_CR38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4143\/crt.2016.057","volume":"49","author":"C Franzese","year":"2017","unstructured":"Franzese C, Franceschini D, Cozzi L, et al. Minimally Invasive Stereotactical Radio-ablation of Adrenal Metastases as an Alternative to Surgery. Cancer Res Treat. 2017;49(1):20\u20138. https:\/\/doi.org\/10.4143\/crt.2016.057 PubMed PMID: 27121718; PubMed Central PMCID: PMCPMC5266381.","journal-title":"Cancer Res Treat"},{"issue":"5","key":"1480_CR39","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3109\/0284186X.2011.652738","volume":"51","author":"M Scorsetti","year":"2012","unstructured":"Scorsetti M, Alongi F, Filippi AR, et al. Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients. Acta Oncol. 2012;51(5):618\u201323. https:\/\/doi.org\/10.3109\/0284186X.2011.652738 PubMed PMID: 22263925.","journal-title":"Acta Oncol"},{"key":"1480_CR40","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3389\/fonc.2019.00732","volume":"9","author":"C Scouarnec","year":"2019","unstructured":"Scouarnec C, Pasquier D, Luu J, et al. Usefulness of Stereotactic Body Radiation Therapy for Treatment of Adrenal Gland Metastases. Front Oncol. 2019;9:732. https:\/\/doi.org\/10.3389\/fonc.2019.00732 PubMed PMID: 31448234; PubMed Central PMCID: PMCPMC6692476.","journal-title":"Front Oncol"},{"issue":"1","key":"1480_CR41","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s13014-018-1152-5","volume":"13","author":"X Zhao","year":"2018","unstructured":"Zhao X, Zhu X, Fei J, et al. Short-term outcomes and clinical efficacy of stereotactic body radiation therapy (SBRT) in treatment of adrenal gland metastases from lung cancer. Radiat Oncol. 2018;13(1):205. https:\/\/doi.org\/10.1186\/s13014-018-1152-5 PubMed PMID: 30348187; PubMed Central PMCID: PMCPMC6196411.","journal-title":"Radiat Oncol"},{"issue":"7 Suppl 3","key":"1480_CR42","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1097\/JTO.0b013e318074de34","volume":"2","author":"H Onishi","year":"2007","unstructured":"Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2(7 Suppl 3):S94\u2013100. https:\/\/doi.org\/10.1097\/JTO.0b013e318074de34 PubMed PMID: 17603311.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"1480_CR43","doi-asserted-by":"publisher","first-page":"e1120","DOI":"10.7759\/cureus.1120","volume":"9","author":"A Haidenberger","year":"2017","unstructured":"Haidenberger A, Heidorn SC, Kremer N, et al. Robotic Radiosurgery for Adrenal Gland Metastases. Cureus. 2017;9(3):e1120. https:\/\/doi.org\/10.7759\/cureus.1120 PubMed PMID: 28451479; PubMed Central PMCID: PMCPMC5406171.","journal-title":"Cureus"},{"issue":"3","key":"1480_CR44","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.radonc.2018.07.025","volume":"129","author":"D Cusumano","year":"2018","unstructured":"Cusumano D, Dhont J, Boldrini L, et al. Predicting tumour motion during the whole radiotherapy treatment: a systematic approach for thoracic and abdominal lesions based on real time MR. Radiother Oncol. 2018;129(3):456\u201362. https:\/\/doi.org\/10.1016\/j.radonc.2018.07.025 PubMed PMID: 30144955.","journal-title":"Radiother Oncol"},{"key":"1480_CR45","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fonc.2015.00185","volume":"5","author":"A Desai","year":"2015","unstructured":"Desai A, Rai H, Haas J, et al. A Retrospective Review of CyberKnife Stereotactic Body Radiotherapy for Adrenal Tumors (Primary and Metastatic): Winthrop University Hospital Experience. Front Oncol. 2015;5:185. https:\/\/doi.org\/10.3389\/fonc.2015.00185 PubMed PMID: 26347852; PubMed Central PMCID: PMCPMC4538288.","journal-title":"Front Oncol"},{"issue":"11","key":"1480_CR46","doi-asserted-by":"publisher","first-page":"e80654","DOI":"10.1371\/journal.pone.0080654","volume":"8","author":"J Li","year":"2013","unstructured":"Li J, Shi Z, Wang Z, et al. Treating adrenal tumors in 26 patients with CyberKnife: a mono-institutional experience. PLoS One. 2013;8(11):e80654. https:\/\/doi.org\/10.1371\/journal.pone.0080654 PubMed PMID: 24278303; PubMed Central PMCID: PMCPMC3835566.","journal-title":"PLoS One"},{"issue":"2","key":"1480_CR47","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ijrobp.2018.06.002","volume":"102","author":"MA Palacios","year":"2018","unstructured":"Palacios MA, Bohoudi O, Bruynzeel AME, et al. Role of daily plan adaptation in MR-guided stereotactic ablative radiation therapy for adrenal metastases. Int J Radiat Oncol Biol Phys. 2018;102(2):426\u201333. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.06.002 PubMed PMID: 29902559.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1480_CR48","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00066-011-2192-z","volume":"187","author":"R Holy","year":"2011","unstructured":"Holy R, Piroth M, Pinkawa M, et al. Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol. 2011;187(4):245\u201351. https:\/\/doi.org\/10.1007\/s00066-011-2192-z PubMed PMID: 21424513.","journal-title":"Strahlenther Onkol"},{"issue":"3","key":"1480_CR49","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.semradonc.2014.02.008","volume":"24","author":"S Mutic","year":"2014","unstructured":"Mutic S, Dempsey JF. The ViewRay system: magnetic resonance-guided and controlled radiotherapy. Semin Radiat Oncol. 2014;24(3):196\u20139. https:\/\/doi.org\/10.1016\/j.semradonc.2014.02.008 PubMed PMID: 24931092.","journal-title":"Semin Radiat Oncol"},{"issue":"23","key":"1480_CR50","doi-asserted-by":"publisher","first-page":"L41","DOI":"10.1088\/1361-6560\/aa9517","volume":"62","author":"BW Raaymakers","year":"2017","unstructured":"Raaymakers BW, Jurgenliemk-Schulz IM, Bol GH, et al. First patients treated with a 1.5 T MRI-Linac: clinical proof of concept of a high-precision, high-field MRI guided radiotherapy treatment. Phys Med Biol. 2017;62(23):L41\u201350. https:\/\/doi.org\/10.1088\/1361-6560\/aa9517 PubMed PMID: 29135471.","journal-title":"Phys Med Biol"},{"issue":"3","key":"1480_CR51","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.radonc.2017.11.032","volume":"126","author":"L Henke","year":"2018","unstructured":"Henke L, Kashani R, Robinson C, et al. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiother Oncol. 2018;126(3):519\u201326. https:\/\/doi.org\/10.1016\/j.radonc.2017.11.032 PubMed PMID: 29277446.","journal-title":"Radiother Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-1480-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13014-020-1480-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-1480-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:29:58Z","timestamp":1612312198000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-020-1480-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,4]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1480"],"URL":"https:\/\/doi.org\/10.1186\/s13014-020-1480-0","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,4]]},"assertion":[{"value":"22 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Heidelberg Ethics Committee approved this study (S-627\/2019).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}